CXCR4 and hematopoietic and lymphoid system neoplasm: CXCR4-targeted molecular imaging has been extensively evaluated across different hematologic and solid neoplasms, and the results indicate that 68Ga-pentixafor may emerge as a novel pan-hematologic tumor agent.